Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors should weigh it alongside other Merck risks. Our analysis turns up 5 warning signs for Merck as well.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.